Story perspectives

FDA Panel Reviews $3B Peptide Market Amid Safety Concerns

7/23/2026

Summary

Story summary

The FDA held a panel on July 22, 2026 to review seven injectable peptides.
Health Secretary Robert F. Kennedy Jr., a self-described “big fan” of peptides, urged loosening restrictions.
Seven of the 14 advisory members have financial ties to peptide clinics or pharmacies.
FDA scientists and the Partnership for Safe Medicines warned the peptides lack safety data, recommending against compounding them due to contamination risks.
The gray market for unregulated peptides is estimated at $3 billion.

1 of 1

Story summary

The FDA held a panel on July 22, 2026 to review seven injectable peptides.
Health Secretary Robert F. Kennedy Jr., a self-described “big fan” of peptides, urged loosening restrictions.
Seven of the 14 advisory members have financial ties to peptide clinics or pharmacies.
FDA scientists and the Partnership for Safe Medicines warned the peptides lack safety data, recommending against compounding them due to contamination risks.
The gray market for unregulated peptides is estimated at $3 billion.